We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+23.66%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.11B
AUM Growth
+$195M
Cap. Flow
+$57.8M
Cap. Flow %
5.19%
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18

Top Buys

1
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.7M
2
ENDP
Endo International plc
ENDP
+$46.9M
3
ALR
Alere Inc
ALR
+$29.1M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$27.8M
5
BIIB icon
Biogen
BIIB
+$21.5M

Top Sells

1
RAD
Rite Aid Corporation
RAD
+$45.4M
2
CELG
Celgene Corp
CELG
+$38.3M
3
GILD icon
Gilead Sciences
GILD
+$34.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
5
AZN icon
AstraZeneca
AZN
+$18.2M

Sector Composition

1 Healthcare 81.12%
2 Financials 2.03%
3 Technology 1.63%
4 Communication Services 1.57%
5 Consumer Staples 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
51
Invesco QQQ Trust
QQQ
$473B
$454K 0.04%
4,300
+866
+25% +$90.9K
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
$241K 0.02%
1,390
– –
CCXI
53
DELISTED
ChemoCentryx, Inc.
CCXI
$132K 0.01%
+17,500
New +$137K
AZN icon
54
AstraZeneca
AZN
$263B
– –
-258,305
Closed -$18.2M
BLUE
55
DELISTED
bluebird bio
BLUE
– –
-7,892
Closed -$9.38M
EHTH icon
56
eHealth
EHTH
$47.3M
– –
-264,942
Closed -$6.6M
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$296M
– –
-1,328
Closed -$3.17M
GILD icon
58
Gilead Sciences
GILD
$169B
– –
-368,615
Closed -$34.7M
IBB icon
59
iShares Biotechnology ETF
IBB
$9.22B
– –
-3,000
Closed -$303K
MCK icon
60
McKesson
MCK
$98.5B
– –
-87,523
Closed -$18.2M
PACB icon
61
Pacific Biosciences
PACB
$463M
– –
-237,977
Closed -$1.87M
PBYI icon
62
Puma Biotechnology
PBYI
$428M
– –
-93,865
Closed -$17.8M
UHS icon
63
Universal Health Services
UHS
$9.29B
– –
-135,270
Closed -$15.1M
NVRO
64
DELISTED
NEVRO CORP.
NVRO
– –
-234,254
Closed -$9.06M
VIRX
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-119
Closed -$64K
RAD
66
DELISTED
Rite Aid Corporation
RAD
– –
-301,937
Closed -$45.4M
WCG
67
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-4,887
Closed -$401K
FWP
68
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-3,605
Closed -$526K
LOXO
69
DELISTED
Loxo Oncology, Inc
LOXO
– –
-137,681
Closed -$1.62M
CNXR
70
DELISTED
Connecture, Inc.
CNXR
– –
-943,000
Closed -$8.5M
CELG
71
DELISTED
Celgene Corp
CELG
– –
-342,349
Closed -$38.3M
1 2
3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2015 Portfolio in Review

As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceuticals: 853,973 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.

  • Redmile Group's largest Q1 2015 buy was Teva Pharmaceuticals: 853,973 shares worth $53.2M.
  • Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
  • Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
  • Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
  • Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
  • Redmile Group opened 18 new positions and closed 18 in Q1 2015.
  • Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.